Hep E vax provides 4 years of protection; Zimbabwe to launch HIV jab trial;

> Novavax ($NVAX) has appointed Brian Rosen as its VP of government affairs. Release

> Targovax is expanding expand an ongoing Phase I/II study of its cancer vaccine candidate. Release

> Scientists in Zimbabwe are preparing to launch the country's first-ever HIV vaccine trial. More

> A vaccine against hepatitis E provided protection against the virus for more than 4 years, researchers say. Report

And Finally... H7N9 bird flu has the makings of a pandemic virus, scientists caution. More

Suggested Articles

Merck & Co. inked a series of deals to advance three COVID-19 projects, trailing some of its large pharma peers into the industrywide research effort.

With a new £131 million contribution from the U.K. government, VMIC aims to both speed up and expand on its prior ambitions.

AstraZeneca scored a $1 billion contribution from the United States for development, production and delivery of its potential COVID-19 vaccine.